Acute Gastroenteritis
Constipation
PEG 3350
The Food and Drug Administration (FDA) has awarded a grant to Children’s Hospital of Philadelphia to study whether there are any adverse effects to prolonged use of PEG 3350 in children with chronic constipation. With the announcement of the study, there has been a new wave of media coverage questioning the safety of Miralax and other laxatives that contain PEG 3350. This media coverage will be accompanied by questions and concerns from parents whose children are being treated effectively for chronic constipation with PEG 3350.
To help pediatric gastroenterologists and pediatricians answer questions, the NASPGHAN Neurogastroenterology and Motility Committee has prepared a frequently asked questions document on PEG 3350.
At this time, there is no evidence to support serious side effects of Miralax and similar products (PEG 3350). Most commonly reported side effects include diarrhea, bloating and nausea. No psychiatric/neurological issues are reported in the scientific literature. Similar to many commonly used medications, the use of Miralax (PEG 3350) is approved by FDA for adults only, due to lack of clinical trials in children. Its metabolism and long-term use in children are being studied. The results from those studies are not likely to be available in the near future. Like all medications, the decision to use Miralax (PEG 3350) should be based on weighing benefits and possible unproven risks. If a parent has concern about the use of Miralax/PEG 3350 for their child’s constipation, they should address it directly with their health care provider.
Diarrhea
Grand Rounds at Primary Children’s Hospital, Salt Lake City, UT–Diagnosis and Management of Carbohydrate-Induced Diarrhea
Support provided by QOL Medical
Endoscopy
The Detection of Small Bowel Mucosal Disease in Children Using Wireless Capsule Endoscopy
IBS
Masqueraders of Irritable Bowel Syndrome
Liver Disease
Publications
Webinar
Primary Sclerosing Cholangitis, Autoimmune Hepatitis and Autoimmune Sclerosing Cholangitis Webinar
Pancreas
Webinar
Exocrine Pancreatic Insufficiency: Diagnosis and Management
Quality Improvement
Module 1- “Quality Improvement 101: How to get started” (narrated by Joshua Gossett, DNP, MBA, RN, FACHE)- duration 17:55
This is a brief introduction on how to begin a quality improvement project and is geared towards all levels of experience and interest. In this first module you will learn how to properly define the problem being addressed, how to properly select a team of individuals, how to map the process of interest and how to construct the aim of the project. A case of “clinic wait time” will be used as an example of how to apply these concepts.
Module 2- “Quality Improvement 102: Making and Sustaining Improvements” (narrated by Beth Williams, BSIE, MBA)- duration 28:49
In this follow up module, viewers will learn additional tools in order to make changes and sustain improvements. Specifically, you will learn how to create a driver diagram, conduct small tests of change called, PDSA’s (plan-do-study-act), analyze run charts and implement changes. The same case of “clinic wait time” will be used to illustrate these points.
